Here are the 10-K annual reports from Aptose Biosciences Inc (APTOF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow APTOF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTOF filings page.
Aptose Biosciences Inc., a clinical-stage oncology biotech focused on hematologic cancers, has agreed to be acquired by Hanmi Pharmaceutical via a Canadian plan of arrangement. Hanmi’s subsidiary will purchase all Aptose common shares it does not already control for C$2.41 in cash per share, with all options, RSUs and warrants cancelled at closing and the shares delisted from the Toronto Stock Exchange.
Shareholders approved the transaction on March 31, 2026, and the outside closing date was extended to June 30, 2026, but completion still depends on regulatory and court approvals and the absence of legal restraints. The company warns that if the deal fails, its business, financial results and share price could be adversely affected and it may need to consider insolvency.
Aptose’s lead asset, tuspetinib, is an oral kinase inhibitor being developed mainly in frontline triple therapy with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia. Across early Phase 1/2 studies, the TUS+VEN+AZA triplet has shown high composite complete remission and minimal residual disease–negative response rates in genetically diverse, often hard‑to‑treat AML patients, with a consistently favorable safety profile.